Dube Eric M 4
4 · Travere Therapeutics, Inc. · Filed Feb 24, 2026
Research Summary
AI-generated summary of this filing
Travere CEO Eric Dube Sells 60,000 Shares After Option Exercise
What Happened
Eric M. Dube, CEO of Travere Therapeutics (TVTX), exercised 60,000 stock options at $15.46 per share (cost $927,600) on Feb 20, 2026, and sold 60,000 shares in the open market that same day for $30.10 per share (proceeds $1,805,766). The Form 4 also reports a 60,000-share derivative disposition at $0; the filing does not provide further detail on that line.
Key Details
- Transaction date: February 20, 2026; Form 4 filed February 24, 2026 (filing within the usual two-business-day window).
- Exercise: 60,000 options (code M) at $15.46 each — total cash paid $927,600. Option is fully vested/exercisable (Footnote F3).
- Sale: 60,000 shares (code S) in an open market sale at a weighted average of $30.0961; reported proceeds $1,805,766. Sale made under a written 10b5-1 plan adopted June 16, 2025 (Footnote F1). Range of sale prices: $30.00–$30.325 (Footnote F2).
- Additional line: 60,000-share derivative conversion/disposition listed at $0 (code M) — filing provides no explanation for this entry.
- Shares owned after the transactions: not specified in the provided filing.
Context
This sequence (exercise of options followed by an immediate sale of the same shares) is common when executives exercise vested options and sell shares to cover costs or diversify; here the sale was executed under a pre-established 10b5-1 plan. The filing is factual and does not state motivation.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-02-20$15.46/sh+60,000$927,600→ 492,886 total - Sale
Common Stock
[F1][F2]2026-02-20$30.10/sh−60,000$1,805,766→ 432,886 total - Exercise/Conversion
Employee stock option (right to buy)
[F3]2026-02-20−60,000→ 60,000 totalExercise: $15.46Exp: 2030-01-31→ Common Stock (60,000 underlying)
Footnotes (3)
- [F1]This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- [F2]The weighted average sale price for the transaction reported was $30.0961, and the range of prices were between $30.00 and $30.325. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]The stock option is fully vested and exercisable.